OneVentures

OneVentures
Name	OneVentures
Type	Private
Industry	Venture capital
Founded	2006
Headquarters	Sydney, Australia
Key people	Stephen Baxter; Simon Moss
Products	Early-stage venture capital, growth equity
Assets	AUM (approximate)

OneVentures OneVentures is an Australian venture capital firm focused on investing in healthcare, technology, and deep tech companies with commercialization potential. The firm targets early-stage and growth-stage opportunities across Australia, New Zealand, and global markets, working with academic institutions, corporate partners, and research organizations to translate innovations into scalable businesses. OneVentures has been active in sectors including biotechnology, medical devices, software, and artificial intelligence, and participates in syndicates with other venture capital firms and institutional investors.

History

OneVentures was founded in 2006 in Sydney amid a period of increasing venture activity alongside firms such as Blackbird Ventures, Main Sequence Ventures, Square Peg Capital, Sequoia Capital, and Accel. The firm’s formation coincided with growth in Australian research commercialization driven by universities like University of Sydney, University of Melbourne, University of New South Wales, and research institutes including CSIRO and Garvan Institute of Medical Research. Over time OneVentures established funds that attracted commitments from superannuation funds, family offices, and corporate investors similar to arrangements seen with AustralianSuper, IFM Investors, and QIC. The firm’s history includes partnerships with healthcare organizations such as Cochrane-style collaborators and involvement in networks with international investors like Temasek, SoftBank Vision Fund, and Index Ventures on select deals. OneVentures’ timeline reflects broader patterns in venture ecosystems charted by commentators such as Rod Searle and analysts from PwC and KPMG.

Investment strategy

OneVentures emphasizes sector specialization and translational investing, aligning with strategies used by firms like Flagship Pioneering and Third Rock Ventures in life sciences, and Andreessen Horowitz and GV in software and AI. The firm seeks companies with defensible intellectual property arising from institutions like Monash University, University of Queensland, and Walter and Eliza Hall Institute and targets capital-efficient pathways to commercialization akin to models pursued by Biocon and Roche spinouts. OneVentures typically co-invests with corporates, family offices, and blue-chip venture funds including Bain Capital Ventures, Temasek, and TPG. The strategy balances risk across seed-stage instruments, convertible notes, Series A equity, and later-stage growth rounds, reflecting structures employed by Y Combinator, 500 Startups, and SOSV.

Portfolio companies

OneVentures’ portfolio spans biotechnology, medical devices, diagnostics, and enterprise software, with examples comparable to companies like Cochlear, ResMed, Atlassian, WiseTech Global, and biotech spinouts resembling CSL Limited’s pathway. Specific portfolio companies have engaged in translational partnerships with hospitals such as Royal Prince Alfred Hospital and St Vincent's Hospital, collaborated with regulators such as Therapeutic Goods Administration, and pursued reimbursement strategies influenced by agencies like Medicare and private insurers. The portfolio includes startups that intersect with artificial intelligence firms like DeepMind-adjacent ventures and medical imaging companies akin to Butterfly Network. Co-investors in these companies have included global venture groups like SV Angel, Lightspeed Venture Partners, Khosla Ventures, and regional players such as Brighte Capital.

Fund structure and financials

OneVentures manages closed-end venture funds with limited partners drawn from institutional investors, family offices, and accredited investors; this model aligns with fund structures used by Blackstone, KKR, and TPG Growth. Fund vintages typically include a five- to ten-year investment period followed by an extended harvest period, mirroring frameworks used by Sequoia Capital and Benchmark. Capital deployment strategies have involved initial seed allocations, follow-on reserves for Series A/B rounds, and participation in later-stage syndicated financings with firms like SoftBank and Tiger Global Management. Financial reporting to limited partners follows standards practiced by ILPA and auditing norms similar to firms audited by Big Four accounting firms such as Deloitte, PwC, and EY.

Management and governance

The firm’s management team is composed of partners and investment professionals with backgrounds in venture capital, medical research, and corporate finance, paralleling career pathways of managers from Domain Holdings Australia, AMP Capital, and Macquarie Group. Governance relies on advisory boards and investment committees akin to structures at Temasek and Commonwealth Bank-backed vehicles. The firm has engaged independent directors and scientific advisors drawn from institutions like Peter Doherty Institute, Baker Heart and Diabetes Institute, and international academia including Harvard Medical School, Stanford University, and MIT.

Notable exits and returns

OneVentures’ realized exits include trade sales and public listings analogous to exits by CSL Limited, Cochlear, and ResMed, with co-investors and acquirers including multinational healthcare corporations such as Roche, Johnson & Johnson, Medtronic, and Novartis. The firm’s exit outcomes have contributed to distributions to limited partners and follow-on fundraising cycles reminiscent of returns reported by Index Ventures and Sequoia Capital. Notable liquidity events in the Australian venture scene include initial public offerings like Atlassian and strategic acquisitions similar to Intel's or Google's corporate M&A, which serve as comparators for OneVentures’ achievements.

Category:Venture capital firms